Mani Foroohar
Stock Analyst at Leerink Swann
(2.21)
# 2,759
Out of 4,915 analysts
166
Total ratings
48.31%
Success rate
-7.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $15.83 | -36.83% | 2 | Jul 21, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Market Perform | $37 → $8 | $3.01 | +165.78% | 12 | May 28, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $19 → $18 | $4.10 | +339.02% | 3 | Mar 24, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $5.95 | +0.84% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $4.36 | +519.27% | 9 | Jan 13, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $21.00 | +242.86% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $1.67 | +917.96% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $51.17 | -4.24% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $46.32 | -0.69% | 15 | Oct 17, 2024 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $22 | $8.32 | +164.42% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $53 → $62 | $41.48 | +49.47% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $11.22 | +15.92% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $21.17 | +36.99% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $5.41 | -26.06% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.41 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $3.46 | +795.95% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.70 | +894.04% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $15.92 | +151.26% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $111 → $93 | $32.66 | +184.75% | 17 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $12.50 | +572.00% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.59 | +170.27% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $19.93 | +286.35% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $330.55 | -56.74% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $6.75 | -11.11% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $59.02 | +28.77% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.96 | +1,634.69% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $2.49 | +704.83% | 6 | Jul 23, 2021 |
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $15.83
Upside: -36.83%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Market Perform
Price Target: $37 → $8
Current: $3.01
Upside: +165.78%
Lexeo Therapeutics
Mar 24, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $4.10
Upside: +339.02%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $5.95
Upside: +0.84%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $4.36
Upside: +519.27%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $21.00
Upside: +242.86%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $1.67
Upside: +917.96%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $51.17
Upside: -4.24%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $46.32
Upside: -0.69%
Wave Life Sciences
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $8.32
Upside: +164.42%
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $41.48
Upside: +49.47%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $11.22
Upside: +15.92%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $21.17
Upside: +36.99%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $5.41
Upside: -26.06%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $8.41
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $3.46
Upside: +795.95%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.70
Upside: +894.04%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $15.92
Upside: +151.26%
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $32.66
Upside: +184.75%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $12.50
Upside: +572.00%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.59
Upside: +170.27%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $19.93
Upside: +286.35%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $330.55
Upside: -56.74%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $6.75
Upside: -11.11%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $59.02
Upside: +28.77%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.96
Upside: +1,634.69%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $2.49
Upside: +704.83%